The pharmaceutical companies BioNTech and Pfizer will invoice 80,449 euros for each of the 525,600 minutes in 2022 for their anti-COVID vaccine

The German company BioNTech and the North American company Pfizer, creators of the “Comirnaty” anti-COVID vaccine, which is how it has been registered with the Food and Drug Authority (FDA), plan to bill for it until a total of 42,284 million euros in 2022.

If we consider that a year is made up of 365 days, or 525,600 minutes, the result of a simple division is 80,449 euros per minute.

Or 1,340.8 euros per second, if we take into account that a year is made up of 31,536,000 seconds.

Ugar Sahin, CEO of BioNTech, revealed on January 11 in the framework of the JP Morgan Annual Health Conference – held virtually – that its revenue forecasts for 2022 for the “Comirnaty” vaccine are between 13,000 and 17,000 millions of euros.

In 2021, it calculates that said income was between 16,000 and 17,000 million euros.

“We expect strong demand to continue this year,” Sahin said.

Pfizer’s forecasts for the current year, whose CEO is Albert Bourla, are around 25,284 million euros [29.000 millones de dólares].

In 2021, its income, according to the projections made by the North American company in the last quarter of that year, would be around 31,383 million euros [36.000 millones de dólares].


If, as the CEO of Pfizer explained, the profits obtained are in the range of 22%, in the case of this company in 2021 they would have been in the range of 7,000 euros.

See also  A child infected with HIV every two minutes

A margin that the Popular Alliance for Vaccines in Africa (People’s Vaccine Alliance), made up of 80 members, including organizations such as the African Alliance, Global Justice Now, Oxfam and UNAIDs, raises up to 77% of what is invoiced.

Or what is the same, 37,254.91 million euros of the 48,383 million entered in 2021.

According to the Alliance, Pfizer, BioNTech and Moderna have all sold most of their doses to rich countries, leaving low-income countries out.

Pfizer and BioNTech have delivered less than one percent of their total vaccine supplies to low-income countries, while Moderna has only delivered 0.2 percent.

Meanwhile, 98% of people in low-income countries have not been fully vaccinated.

Maaza Seyoum, of the African Alliance and the People’s Alliance for Vaccination in Africa told “reliefweb”: “It is obscene that a few companies make millions of dollars in profits every hour, while only two percent of the people in the countries low-income have been fully vaccinated against the coronavirus.”

“Pfizer, BioNTech and Moderna have used their monopolies to prioritize the most profitable contracts with the richest governments, leaving out low-income countries.”

Anna Marriott, responsible for health policies at Oxfam, for his part, stated, in the same medium, that «Contrary to what the CEO of Pfizer says, the real nonsense is to affirm that in developing countries there is no experience and the knowledge needed to develop and manufacture life-saving medicines and vaccines. This is nothing more than a false excuse that pharmaceutical companies hide behind to protect their astronomical profits.

See also  Cupra Born for sale, starting at 38,900 euros

He added: “It is also a complete failure of the government to allow these companies to maintain monopoly control and artificially restrict supply in the midst of a pandemic while so many people in the world have yet to be vaccinated.”

This news talks about:

Related news:

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.